Profil
Sophia Paspal worked as a Director of Regulatory Affairs & Oncology at Halozyme Therapeutics, Inc. from 2015 to 2017.
Prior to that, she was an Associate Director of Regulatory Affairs & Neurology at Dart NeuroScience LLC in 2014-2015.
Dr. Paspal also served as the Chief Development Officer at Xynomic Pharmaceuticals Holdings, Inc. Dr. Paspal received her undergraduate and doctorate degrees from the University of Minnesota.
Anciens postes connus de Sophia Paspal
| Sociétés | Poste | Fin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2017 |
Dart NeuroScience LLC
 Dart NeuroScience LLC Pharmaceuticals: MajorHealth Technology Dart NeuroScience LLC develops drugs to improve memory. The private company is based in San Diego, CA. The CEO of the company is Kenneth E. Johns. | Corporate Officer/Principal | 01/01/2015 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Sophia Paspal
| University of Minnesota | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Dart NeuroScience LLC
Dart NeuroScience LLC Pharmaceuticals: MajorHealth Technology Dart NeuroScience LLC develops drugs to improve memory. The private company is based in San Diego, CA. The CEO of the company is Kenneth E. Johns. | Health Technology |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
